Zydus receives WHO prequalification for Vaxirab – N
February 10, 2019
Geneva, 07 February 2019 – Vaxirab N, the purified chick embryo cell rabies vaccine manufactured by Zydus Cadila, a leading innovation-driven global healthcare provider, has received prequalification from the World Health Organization (WHO).
In 2008, the group received WHO prequalification for its purified duck embryo rabies vaccine, Lyssavac N – the (PDEV), for purchase by various United Nations Agencies. With this, Zydus became the first Indian Pharma company, and the second pharma company in the world, to receive WHO prequalification for rabies vaccine. Zydus subsequently migrated to the purified chick embryo cell rabies vaccine, Vaxirab N, which received WHO prequalification on 07 February 2019, and shall contribute to global supply to save lives and achieve the goal set by WHO, aiming zero human deaths from rabies by 2030.
Zydus Cadila develops vaccines for routine vaccination programmes such as Diphtheria, Pertussis, Tetanus, Haemophilus Influenzae type B, Hepatitis B, Measles, Mumps, Rubella, Varicella, Influenza and Typhoid fever. In addition, VTC is developing new vaccines such as Human Papilloma Virus, Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola and Japanese Encephalitis.
